Dabrafenib–trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer
European Journal of Cancer2020Vol. 143, pp. 31–32
Citations Over Time
Related Papers
- → Trametinib: a MEK inhibitor for management of metastatic melanoma(2015)177 cited
- → Trametinib in the treatment of melanoma(2015)39 cited
- → Dabrafenib–trametinib combination therapy re-challenge in advanced BRAFV600E-mutant non–small-cell lung cancer(2020)12 cited
- → BRAF and MEK Inhibitors Approved for Melanoma(2013)1 cited
- → The MEK inhibitor trametinib for the treatment of advanced melanoma(2014)